Oragenics announced Wednesday that it has been approved in Belgium to enroll patients in its Phase 2 trial for its drug AG013 for a mouth disorder, Oral Mucositis.
The post Oragenics Receives Approval for Phase 2 Study appeared first on Investing News Network.
Original Article: Oragenics Receives Approval for Phase 2 Study